Company Description
Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs.
The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target.
Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2.
Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021.
The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020.
The company was incorporated in 2019 and is based in Boston, Massachusetts.
| Country | United States |
| Founded | 2019 |
| IPO Date | Jun 25, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 29 |
| CEO | Ryan Bloomer |
Contact Details
Address: 101 Federal Street, Suite 1900 Boston, Massachusetts 02110 United States | |
| Phone | (716) 371-1125 |
| Website | elevationoncology.com |
Stock Details
| Ticker Symbol | ELEV |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001783032 |
| CUSIP Number | 28623U101 |
| ISIN Number | US28623U1016 |
| Employer ID | 84-1771427 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. David Dornan Ph.D. | Chief Scientific Officer |
| Valerie Malyvanh Jansen M.D., Ph.D. | Chief Medical Officer |
| Joseph J. Ferra Jr. | Chief Executive Officer, President and Director |
| Tammy Furlong CPA, P.M.P. | Chief Financial Officer and Secretary |
| Ryan Bloomer | Head of Tech Ops |
| Candice Masse | Senior Director of Corporate Communications and Investor Relations |
| Robert C. Yang | Vice President of Legal Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 2, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| May 2, 2024 | 8-K | Current Report |
| May 2, 2024 | 10-Q | Quarterly Report |
| Apr 26, 2024 | ARS | Filing |
| Apr 26, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 26, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 9, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Apr 5, 2024 | 8-K | Current Report |
| Mar 6, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 6, 2024 | 8-K | Current Report |